Engitix secures £18.6m in Series A extension financing led by Netherton Investments
The financing was provided by Netherton Investments to advance extracellular matrix-targeted treatments for solid tumours and fibrosis.
Engitix is a biotechnology company focused on extracellular matrix targets to develop therapies for cancer and fibrosis. It operates from London and maintains partnerships with major pharmaceutical firms.
Engitix has raised £18.6m in a Series A extension financing round led by Netherton Investments. The funding will support the continued preclinical development of the company pipeline targeting the extracellular matrix in solid tumours and fibrosis, alongside the expansion of its proprietary data platform.
The investment builds on existing backing from Mike Platt and follows earlier partnerships established with firms such as Takeda and Dompé farmaceutici. Engitix aims to use the capital to translate its high-resolution extracellular matrix datasets into precision therapeutics designed for diseased tissue microenvironments.
From the founder
"Closing this financing strengthens our ability to translate Engitix's unique ECM understanding into a growing pipeline of targeted therapeutics."
Giuseppe Mazza
CEO at Engitix
Investor perspective
"Engitix has developed a compelling strategy at the intersection of data, biology, and drug development. I'm pleased to continue supporting Engitix as it advances its programs in fibrosis and solid tumors."
Mike Platt
Investor Director, Netherton Investments
Use of funds
- 01Fund research and development
- 02Continue product development
Investors
Categories
About the company
Engitix
Engitix builds extracellular matrix datasets to develop targeted therapies for cancer and fibrosis.